CompletedPhase 2NCT00031993
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Studying Squamous cell carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Russell Schilder, M.DGynecologic Oncology Group
- Intervention
- erlotinib hydrochloride(drug)
- Enrollment
- 51 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2002
Study locations (1)
- Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00031993 on ClinicalTrials.gov